Chronic liver disease is a major health problem that affects millions of people around the world. The liver is one of the body’s most important organs.
It removes toxins from the blood, stores nutrients, helps digest food, produces proteins needed for blood clotting, and plays a key role in many other body functions.
When the liver is damaged over many months or years, healthy tissue is gradually replaced by scar tissue. This process is called fibrosis. As the scarring becomes more severe, it develops into cirrhosis, a condition in which the liver can no longer work properly.
One of the most dangerous complications of cirrhosis is portal hypertension. This happens when scar tissue blocks the normal flow of blood through the liver. As a result, pressure builds up in the portal vein, the large blood vessel that carries blood from the stomach and intestines to the liver.
High pressure in this vein can cause swollen veins in the food pipe or stomach, known as varices, which may suddenly bleed and become life-threatening. It can also lead to fluid collecting in the abdomen, called ascites, and a brain condition known as hepatic encephalopathy, where toxins that should have been removed by the liver affect thinking and memory.
Now, researchers from MedUni Vienna have discovered that a group of medicines already used to treat portal hypertension may provide another important benefit.
Their study suggests that beta-blockers not only reduce pressure in the portal vein but may also lower harmful inflammation throughout the body. The research was led by Thomas Reiberger and published in the journal Gut.
Beta-blockers have been used for many years to treat portal hypertension because they reduce blood flow into the portal vein, lowering pressure and reducing the risk of dangerous bleeding. However, doctors have known that these medicines do not work equally well for everyone. Only about half of patients achieve the desired reduction in portal pressure.
The new study helps explain why beta-blockers may still provide important benefits beyond lowering blood pressure inside the liver.
The researchers examined markers of inflammation before and after patients started treatment. They found that people with advanced cirrhosis often had high levels of systemic inflammation, meaning inflammation that affects the entire body rather than just the liver.
Systemic inflammation is increasingly recognized as a major driver of liver disease progression. It can damage organs, weaken the immune system, increase the risk of infections, and contribute to liver failure. Scientists believe that reducing this inflammation may improve survival and lower the risk of serious complications.
The researchers found that patients treated with beta-blockers showed lower levels of inflammation after starting therapy. For example, they had lower white blood cell counts, which often reflect reduced inflammation. They also experienced fewer complications related to portal hypertension and had a lower risk of death than expected.
The study also showed a close relationship between portal hypertension and inflammation. As pressure in the portal vein increased, inflammation throughout the body also became more severe. This finding suggests that reducing portal pressure may also help calm the inflammatory processes that worsen liver disease.
These results may eventually help doctors identify which patients are most likely to benefit from beta-blocker treatment. Instead of using the same approach for everyone, future care may become more personalized based on the degree of liver scarring, portal pressure, and inflammation.
Although the findings are encouraging, patients should never start, stop, or change beta-blocker treatment without medical advice. These medicines are not suitable for everyone, and doctors carefully consider blood pressure, kidney function, heart health, and other medical conditions before prescribing them.
Chronic liver disease has many causes. Heavy alcohol use, chronic hepatitis B or hepatitis C infection, metabolic dysfunction-associated fatty liver disease, autoimmune liver diseases, and inherited conditions can all lead to long-term liver damage.
Preventing liver disease by limiting alcohol, maintaining a healthy weight, controlling diabetes, and receiving appropriate medical care remains extremely important.
For people who already have advanced liver disease, treatment often includes lifestyle changes, medicines such as beta-blockers, regular monitoring for complications, and sometimes liver transplantation in severe cases.
This new research offers hope that an inexpensive medicine already used in everyday medical practice may provide broader protection than previously understood.
By reducing both portal hypertension and harmful inflammation, beta-blockers could help improve the outlook for many people living with advanced liver disease. Larger studies will continue to explore these benefits and help doctors provide the safest and most effective treatment for each patient.
If you care about high blood pressure, please read studies that early time-restricted eating could help improve blood pressure, and natural coconut sugar could help reduce blood pressure and artery stiffness.
For more information about blood pressure, please see recent studies about How to eat your way to healthy blood pressure and results showing that Modified traditional Chinese cuisine can lower blood pressure.
The research was published in the journal Gut.
